Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 17/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943444 | 0.76 | HSP90AA1 (1.00) | HSP90AB1HSP90AA1KDM4E | |
| SCHEMBL4735379 | 0.74 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1CYP2C19KCNH2DHFR | |
| SCHEMBL3947284 | 0.74 | HSP90AB1 (0.61) | HSP90AB1HSP90AA1DHFRKDM4EKMT2A | |
| SCHEMBL3943328 | 0.73 | HSP90AA1 (0.60) | HSP90AB1HSP90AA1KDM4E | |
| SCHEMBL3944554 | 0.73 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1KDM4E | |
| SCHEMBL4186649 | 0.72 | HSP90AB1 (0.70) | HSP90AB1HSP90AA1CYP2C19KCNH2 | |
| SCHEMBL4184184 | 0.71 | HSP90AB1 (0.69) | HSP90AB1HSP90AA1CYP2C19KCNH2 | |
| SCHEMBL4184134 | 0.71 | HSP90AB1 (0.66) | HSP90AB1HSP90AA1CYP2C19KCNH2 | |
| SCHEMBL4193011 | 0.71 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1CYP2C19KCNH2 | |
| SCHEMBL15613048 | 0.71 | HSP90AB1 (0.54) | HSP90AB1HSP90AA1CYP2C19KCNH2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-2049497-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2006123165-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885CYP2C19 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.